{"id":35869,"date":"2025-12-05T09:05:41","date_gmt":"2025-12-05T15:05:41","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=35869"},"modified":"2025-12-05T09:05:41","modified_gmt":"2025-12-05T15:05:41","slug":"brakke-viewpoint-december-5-2025","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-december-5-2025\/","title":{"rendered":"Mirante de Brakke 5 de dezembro de 2025"},"content":{"rendered":"<p>Ao longo da minha carreira, tenho analisado de perto a inova\u00e7\u00e3o no setor de sa\u00fade animal. Recentemente, tenho refletido sobre como os avan\u00e7os e a ado\u00e7\u00e3o da intelig\u00eancia artificial (IA) podem otimizar o processo de descoberta de medicamentos.<\/p>\n<p>Muitas startups hoje enfatizam o uso de IA para melhorar a efici\u00eancia, a velocidade e a rela\u00e7\u00e3o custo-benef\u00edcio. O que me interessa entender \u00e9 como a IA pode analisar conjuntos de dados massivos, resultados de ensaios cl\u00ednicos e informa\u00e7\u00f5es gen\u00e9ticas para propor novos candidatos a medicamentos. Isso pode levar a uma melhor modelagem preditiva, reduzindo assim os prazos de desenvolvimento e os custos associados.<\/p>\n<p>Esta semana, um webcast sobre inova\u00e7\u00e3o da Zoetis \u2014 a maior empresa de sa\u00fade animal do mundo \u2014 ofereceu informa\u00e7\u00f5es sobre aplica\u00e7\u00f5es pr\u00e1ticas de IA em pesquisa e desenvolvimento. O Dr. Robert Polzer, Vice-Presidente Executivo e Presidente de P&amp;D da Zoetis, destacou quatro \u00e1reas principais onde a IA est\u00e1 sendo utilizada atualmente: identifica\u00e7\u00e3o de alvos, sele\u00e7\u00e3o de candidatos, gerenciamento de ensaios cl\u00ednicos e gera\u00e7\u00e3o de relat\u00f3rios.<\/p>\n<p>Embora a Zoetis esteja de olho em oportunidades significativas, ser\u00e1 que a IA poder\u00e1 se tornar uma ferramenta valiosa para o desenvolvimento de novos tratamentos para doen\u00e7as raras e esp\u00e9cies menos desenvolvidas? Espero que sim. Al\u00e9m disso, a IA pode ajudar a reduzir os testes em animais, abrir caminho para a medicina veterin\u00e1ria de precis\u00e3o e permitir o c\u00e1lculo da farmacocin\u00e9tica entre esp\u00e9cies com o aux\u00edlio da IA.<\/p>\n<p>Apesar das preocupa\u00e7\u00f5es com a satura\u00e7\u00e3o da IA, parece que a jornada est\u00e1 apenas come\u00e7ando e h\u00e1 muito mais potencial a ser explorado na interse\u00e7\u00e3o entre IA e inova\u00e7\u00e3o.<\/p>\n<p><em>Dr. Chuck Johnson<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Ao longo da minha carreira, tenho examinado atentamente a inova\u00e7\u00e3o no setor de sa\u00fade animal. Recentemente, tenho refletido sobre como os avan\u00e7os e a ado\u00e7\u00e3o da intelig\u00eancia artificial (IA) podem otimizar o processo de descoberta de medicamentos. Muitas startups hoje enfatizam o uso da IA para melhorar a efici\u00eancia, a velocidade e a rela\u00e7\u00e3o custo-benef\u00edcio. O que me interessa compreender \u00e9 como a IA pode analisar conjuntos de dados massivos, resultados de ensaios cl\u00ednicos e informa\u00e7\u00f5es gen\u00e9ticas para propor novos candidatos a medicamentos. Isso pode levar a uma melhor modelagem preditiva, reduzindo, assim, os prazos de desenvolvimento e os custos associados. Esta semana, um webcast sobre inova\u00e7\u00e3o da Zoetis \u2014 a maior empresa de sa\u00fade animal do mundo \u2014 ofereceu insights sobre aplica\u00e7\u00f5es pr\u00e1ticas de IA em pesquisa e desenvolvimento. O Dr. Robert Polzer, Vice-Presidente Executivo e Presidente de P&amp;D da Zoetis, destacou quatro \u00e1reas-chave onde a IA est\u00e1 sendo utilizada atualmente: identifica\u00e7\u00e3o de alvos, sele\u00e7\u00e3o de candidatos, gerenciamento de ensaios cl\u00ednicos e gera\u00e7\u00e3o de relat\u00f3rios. Embora a Zoetis esteja de olho em oportunidades significativas, ser\u00e1 que a IA poder\u00e1 se tornar uma ferramenta valiosa para o desenvolvimento de novos tratamentos para doen\u00e7as raras e esp\u00e9cies menos amea\u00e7adas? Espero que sim. Al\u00e9m disso, a IA pode ajudar a reduzir os testes em animais, abrir caminho para a medicina veterin\u00e1ria de precis\u00e3o e permitir o c\u00e1lculo da farmacocin\u00e9tica entre esp\u00e9cies com base em IA. Apesar das preocupa\u00e7\u00f5es com a satura\u00e7\u00e3o da IA, parece que a jornada est\u00e1 apenas come\u00e7ando e h\u00e1 muito mais potencial a ser explorado na interse\u00e7\u00e3o entre IA e inova\u00e7\u00e3o. Dr. Chuck Johnson<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-35869","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-december-5-2025\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"Throughout my career, I have closely examined innovation within the animal health sector. Recently, I have been considering how advancements and adoption of artificial intelligence (AI) could streamline the drug discovery process. Many startups today emphasize their use of AI to improve efficiency, speed, and cost-effectiveness. What I am eager to understand is how AI can analyze massive datasets, clinical trial results, and genetic information to propose new drug candidates. This can lead to better predictive modeling, thereby reducing development timelines and associated costs. This week, an Innovation webcast from Zoetis\u2014the world&#8217;s largest animal health company\u2014provided insight into practical AI applications in research and development. Dr. Robert Polzer, Executive Vice President and President of R&amp;D at Zoetis, highlighted four key areas where AI is currently being utilized: target identification, candidate selection, clinical trial management, and report generation. While Zoetis is targeting significant opportunities, could AI become a valuable tool for developing new treatments for orphan diseases and minor species? I hope so. Additionally, AI may help reduce animal testing, pave the way for veterinary precision medicine, and enable AI-driven computation of cross-species pharmacokinetics. Despite concerns about AI fatigue, it appears that the journey is just beginning, and there is much more potential to be realized in the intersection of AI and Innovation. Dr. Chuck Johnson\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-december-5-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-05T15:05:41+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint December 5, 2025\",\"datePublished\":\"2025-12-05T15:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/\"},\"wordCount\":223,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/\",\"url\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2025-12-05T15:05:41+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint December 5, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-december-5-2025\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"Throughout my career, I have closely examined innovation within the animal health sector. Recently, I have been considering how advancements and adoption of artificial intelligence (AI) could streamline the drug discovery process. Many startups today emphasize their use of AI to improve efficiency, speed, and cost-effectiveness. What I am eager to understand is how AI can analyze massive datasets, clinical trial results, and genetic information to propose new drug candidates. This can lead to better predictive modeling, thereby reducing development timelines and associated costs. This week, an Innovation webcast from Zoetis\u2014the world&#8217;s largest animal health company\u2014provided insight into practical AI applications in research and development. Dr. Robert Polzer, Executive Vice President and President of R&amp;D at Zoetis, highlighted four key areas where AI is currently being utilized: target identification, candidate selection, clinical trial management, and report generation. While Zoetis is targeting significant opportunities, could AI become a valuable tool for developing new treatments for orphan diseases and minor species? I hope so. Additionally, AI may help reduce animal testing, pave the way for veterinary precision medicine, and enable AI-driven computation of cross-species pharmacokinetics. Despite concerns about AI fatigue, it appears that the journey is just beginning, and there is much more potential to be realized in the intersection of AI and Innovation. Dr. Chuck Johnson","og_url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-december-5-2025\/","og_site_name":"Brakke Consulting Website","article_published_time":"2025-12-05T15:05:41+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Amanda McDavid","Tempo estimado de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint December 5, 2025","datePublished":"2025-12-05T15:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/"},"wordCount":223,"articleSection":["Viewpoints"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/","url":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2025-12-05T15:05:41+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-december-5-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint December 5, 2025"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"Amanda McDavid","url":"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/35869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=35869"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/35869\/revisions"}],"predecessor-version":[{"id":35872,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/35869\/revisions\/35872"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=35869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=35869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=35869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}